Lilly: Zepbound Shows Greater Weight Loss Than Wegovy HD In New Analysis

Eli Lilly's shares rose 1% after data showed its oral treatment, Foundayo, achieved greater weight and blood-sugar reductions than oral semaglutide in a 52-week study. The findings were presented at the European Association for the Study of Diabetes meeting. The data is not from a direct head-to-head trial.

Novo Nordisk (NYSE:NVO) reported that increasing semaglutide dosage reduced major cardiovascular events by 6% compared to switching to Eli Lilly's (NYSE:LLY) tirzepatide. The study involved 636,525 type 2 diabetes patients. Novo also licensed HRS-1596 from Hengrui Pharma for up to $2.6 billion, targeting obesity and type 2 diabetes. NVO shares fell 1.34% to $38.19 on Tuesday.

Novo Nordisk presented data showing Ozempic at 2 mg reduced cardiovascular risk vs. switching to Eli Lilly's Mounjaro. Eli Lilly countered with data suggesting Zepbound led to greater weight loss than Wegovy HD. Both companies made claims at a diabetes conference.

Eli Lilly (LLY) presented data showing its weight-loss drug Zepbound outperformed Novo Nordisk's (NVO) Wegovy in weight reduction and blood sugar control. At 72 weeks, 15 mg Zepbound led to 4.5% more weight loss than Wegovy HD. Foundayo, another Lilly drug, also showed superior results over oral semaglutide in type 2 diabetes management. LLY shares rose 0.36% premarket, while NVO fell 1.38%.

Eli Lilly (LLY) reported that its obesity drug Zepbound showed superior weight loss results compared to Novo Nordisk's Wegovy HD in a clinical study. Patients on Zepbound lost 3.2% to 4.5% body weight, with higher doses achieving 20%+ weight reduction three times more often. LLY is trading at a 24.1% discount to its GF Value of $1559.98, with a GF Score of 96/100.

Eli Lilly reported an indirect analysis showing Zepbound 10 mg and 15 mg were associated with greater weight loss than Wegovy HD 7.2 mg in adults with obesity. At 72 weeks, Zepbound 15 mg showed 4.5% greater average weight loss. The comparison used data from separate trials, not a direct head-to-head study.